Non-severe hypoglycemia in type 1 diabetes: a randomized crossover trial comparing two quantities of oral carbohydrates at different insulin-induced hypoglycemia ranges

被引:1
|
作者
Taleb, Nadine [1 ,2 ,3 ]
Gingras, Veronique [1 ,4 ,5 ]
Cheng, Ran [1 ,3 ]
Parent, Valerie [1 ]
Messier, Virginie [1 ]
Bovan, Danijela [1 ]
Shohoudi, Azadeh [1 ]
Brazeau, Anne-Sophie [6 ,7 ]
Rabasa-Lhoret, Remi [1 ,3 ,5 ,7 ]
机构
[1] Montreal Clin Res Inst, Montreal, PQ, Canada
[2] Univ Montreal, Fac Med, Biomed Sci Dept, Montreal, PQ, Canada
[3] Ctr Hosp Univ Montreal, Endocrinol Div, Montreal, PQ, Canada
[4] CHU St Justine, Res Ctr, Montreal, PQ, Canada
[5] Univ Montreal, Fac Med, Dept Nutr, Montreal, PQ, Canada
[6] McGill Univ, Sch Human Nutr, Montreal, PQ, Canada
[7] Montreal Diabet Res Ctr, Montreal, PQ, Canada
来源
基金
加拿大健康研究院;
关键词
non-severe hypoglycemia; hypoglycemia treatment guidelines; type; 1; diabetes; oral carbohydrate; subcutaneous insulin injection; ADULTS;
D O I
10.3389/fendo.2023.1186680
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsNon-severe hypoglycemia (NS-H) is challenging for people living with type 1 diabetes (PWT1D) and often results from relative iatrogenic hyper-insulinemia. Current guidelines recommend a one-size-fits-all approach of 15-20 g of simple carbohydrates (CHO) every 15 min regardless of the triggering conditions of the NS-H event. We aimed to test different amounts of CHO to treat insulin-induced NS-H at various glucose ranges. MethodsThis is a randomized, four-way, crossover study involving PWT1D, testing NS-H treatment outcomes with 16 g vs. 32 g CHO at two plasma glucose (PG) ranges: A: 3.0-3.5 mmol/L and B: <3.0 mmol/L. Across all study arms, participants consumed an additional 16 g of CHO if PG was still <3.0 mmol/L at 15 min and <4.0 mmol/L at 45 min post-initial treatment. Subcutaneous insulin was used in a fasting state to induce NS-H. Participants had frequent venous sampling of PG, insulin, and glucagon levels. ResultsParticipants (n = 32; 56% female participants) had a mean (SD) age of 46.1 (17.1) years, had HbA1c at 54.0 (6.8 mmol/mol) [7.1% (0.9%)], and had a diabetes duration of 27.5 (17.0) years; 56% were insulin pump users. We compared NS-H correction parameters between 16 g and 32 g of CHO for range A, 3.0-3.5 mmol/L (n = 32), and range B, <3.0 mmol/L (n = 29). Change in PG at 15 min for A: 0.1 (0.8) mmol/L vs. 0.6 (0.9) mmol/L, p = 0.02; and for B: 0.8 (0.9) mmol/L vs. 0.8 (1.0) mmol/L, p = 1.0. Percentage of participants with corrected episodes at 15 min: (A) 19% vs. 47%, p = 0.09; (B) 21% vs. 24%, p = 1.0. A second treatment was necessary in (A) 50% vs. 15% of participants, p = 0.001; (B) 45% vs. 34% of participants, p = 0.37. No statistically significant differences in insulin and glucagon parameters were observed. ConclusionsNS-H, in the context of hyper-insulinemia, is difficult to treat in PWT1D. Initial consumption of 32 g of CHO revealed some advantages at the 3.0-3.5 mmol/L range. This was not reproduced at lower PG ranges since participants needed additional CHO regardless of the amount of initial consumption.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
    Rickels, Michael R.
    Ruedy, Katrina J.
    Foster, Nicole C.
    Piche, Claude A.
    Dulude, Helene
    Sherr, Jennifer L.
    Tamborlane, William V.
    Bethin, Kathleen E.
    DiMeglio, Linda A.
    Wadwa, R. Paul
    Ahmann, Andrew J.
    Haller, Michael J.
    Nathan, Brandon M.
    Marcovina, Santica M.
    Rampakakis, Emmanouil
    Meng, Linyan
    Beck, Roy W.
    DIABETES CARE, 2016, 39 (02) : 264 - 270
  • [2] Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
    Belfort-DeAguiar, Renata D.
    Naik, Sarita
    Hwang, Janice
    Szepietowska, Barbara
    Sherwin, Robert S.
    DIABETES CARE, 2015, 38 (09) : 1736 - 1741
  • [3] Low-Dose Dasiglucagon vs. Oral Carbohydrates for Prevention of Insulin-Induced Hypoglycemia in People with Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover
    Laugesen, Christian
    Ranjan, Ajenthen
    Schmidt, Signe
    Norgaard, Kirsten
    DIABETES, 2021, 70
  • [4] Effects of oral aminoacids on counterregulatory responses to insulin-induced hypoglycemia in type 1 diabetes mellitus
    Fanelli, CG
    Rossetti, P
    Porcellati, F
    Marzotti, S
    Bolli, GB
    DIABETOLOGIA, 2005, 48 : A293 - A293
  • [5] Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes
    Zhong, Victor W.
    Crandell, Jamie L.
    Shay, Christina M.
    Gordon-Larsen, Penny
    Cole, Stephen R.
    Juhaeri, Juhaeri
    Kahkoska, Anna R.
    Maahs, David M.
    Seid, Michael
    Forlenza, Gregory P.
    Mayer-Davis, Elizabeth J.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (08) : 1340 - 1347
  • [6] Sustained Efficacy of Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Subjects with Recurrent Non-Severe and Severe Hypoglycemia and Hypoglycemia Unawareness: A Pilot Study
    Gimenez, Marga
    Lara, Merce
    Conget, Ignacio
    DIABETES TECHNOLOGY & THERAPEUTICS, 2010, 12 (07) : 517 - 521
  • [7] Oral aminoacids sustain cognitive function during insulin-induced hypoglycemia in type 1 diabetes mellitus
    Porcellati, F
    Rossetti, P
    Fanelli, CG
    Ricci, NB
    Aglietti, C
    Bolli, GB
    DIABETOLOGIA, 2005, 48 : A292 - A292
  • [8] The effects of insulin-induced hypoglycemia on psychomotor function in adults with type 1 diabetes
    Geddes, Jacqueline
    Deary, Ian J.
    Frier, Brian M.
    DIABETES, 2007, 56 : A168 - A168
  • [9] Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial
    Cheng, Ran
    Taleb, Nadine
    Wu, Zekai
    Bouchard, Delphine
    Parent, Valerie
    Lalanne-Mistrih, Marie-Laure
    Boudreau, Valerie
    Messier, Virginie
    Lacombe, Marie-Josee
    Grou, Caroline
    Brazeau, Anne-Sophie
    Rabasa-Lhoret, Remi
    DIABETES CARE, 2024, 47 (03) : 476 - 482
  • [10] Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States
    Foos, Volker
    Varol, Nebibe
    Curtis, Bradley H.
    Boye, Kristina S.
    Grant, David
    Palmer, James L.
    McEwan, Phil
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (06) : 420 - 432